⬡ Featured Deep Dive · March 2026
The ANKTIVA Thesis:
A Biotech Inflection Case
From $14M to $113M in one year. NCCN listed. 33 countries approved. Is ImmunityBio's bladder cancer drug the start of something much bigger?
Latest Analysis
🔬 Deep Dive · Biotech · Interactive Model
$IBRX Valuation Model: What Insurance Coverage Does to the Bull Case
NCCN's March 2026 guideline update opens the door to payer reimbursement. We modeled three scenarios — base ($15), bull ($45), and bear ($5) — and what BCG-naïve approval could mean for share price by 2028.
Coming Up
Deep Dive · Small Cap · Drones
$ONDS — Drone Dominance: The Infrastructure Play Nobody Is Talking About
While the market chases flashy drone manufacturers, Ondas is quietly becoming the backbone of autonomous drone infrastructure. Here's why the picks-and-shovels play might be the smarter bet.
Soon